Abstract
Heat shock protein 90 (Hsp90), a 90-kDa molecular chaperone, is responsible for biological activities of key signaling molecules (clients) such as protein kinases, ubiquitin ligases, steroid receptors, cell cycle regulators, and transcription factors regulating various cellular processes, including growth, survival, differentiation, and apoptosis. Because Hsp90 is also involved in stabilization of oncogenic ‘client’ proteins, its specific chaperone activity blockers are currently being tested as anticancer agents in advanced clinical trials. Recent in vitro and in vivo studies have shown that Hsp90 is also involved in activation of innate and adaptive cells of the immune system. For these reasons, pharmacological inhibition of Hsp90 has been evaluated in murine models of autoimmune and inflammatory diseases. This mini-review summarizes current knowledge of the effects of Hsp90 inhibitors on autoimmune and inflammatory diseases’ features and is based solely on preclinical studies.
Similar content being viewed by others
References
Ambade A, Catalano D, Lim A, Kopoyan A, Shaffer SA, Mandrekar P (2014) Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury. J Hepatol 61:903–911
Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC (2013) Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol 190:1360–1371
Barbatis C, Tsopanomichalou M (2009) Heat shock proteins in inflammatory bowel disease. Ann Gastroenterol 22:244–247
Borges TJ, Wieten L, van Herwijnen MJ, Broere F, van der Zee R, Bonorino C, van Eden W (2012) The anti-inflammatory mechanisms of Hsp70. Front Immunol 3:95
Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G, Snead C, Cannon J, Venema RC, Catravas JD (2007) Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med 176:667–675
Collins CB, Aherne CM, Yeckes A, Pound K, Eltzschig HK, Jedlicka P, de Zoeten EF (2013) Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function. Mucosal Immunol 6:960–971
Constantinescu CS, Farooqi N, O’Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164:1079–1106
Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340–350
Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL (2006) The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem 99:1351–1362
Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO (2000) The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 275:3305–3312
Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361
Garcia-Carbonero R, Carnero A, Paz-Ares L (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14:e358–e369
Han JM, Kwon NH, Lee JY, Jeong SJ, Jung HJ, Kim HR, Li Z, Kim S (2010) Identification of gp96 as a novel target for treatment of autoimmune disease in mice. PLoS One 5, e9792
Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford EA, Cheetham ME, Chen B, Hightower LE (2009) Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 14:105–111
Kasperkiewicz M, Schmidt E (2009) Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 6:270–280
Kasperkiewicz M, Muller R, Manz R, Magens M, Hammers CM et al (2011) Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood 117:6135–6142
Langer T, Rosmus S, Fasold H (2003) Intracellular localization of the 90 kDA heat shock protein (HSP90alpha) determined by expression of a EGFP-HSP90alpha-fusion protein in unstressed and heat stressed 3T3 cells. Cell Biol Int 27:47–52
Li J, Buchner J (2013) Structure, function and regulation of the hsp90 machinery. Biomed J 36:106–117
Li W, Tsen F, Sahu D, Bhatia A, Chen M, Multhoff G, Woodley DT (2013) Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int Rev Cell Mol Biol 303:203–235
Lilja A, Weeden CE, McArthur K, Nguyen T, Donald A, Wong ZX, Dousha L, Bozinovski S, Vlahos R, Burns CJ, Asselin-Labat ML, Anderson GP (2015) HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo. PLoS One 10, e0114975
Ludwig RJ, Zillikens D (2011) Pathogenesis of epidermolysis bullosa acquisita. Dermatol Clin 29:493–501
Mazzarella RA, Green M (1987) ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J Biol Chem 262:8875–8883
McConnell JR, Buckton LK, McAlpine SR (2015) Regulating the master regulator: controlling heat shock factor 1 as a chemotherapy approach. Bioorg Med Chem Lett 25:3409–3414
Mollapour M, Neckers L (2012) Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta 1823:648–655
Monrad S, Kaplan MJ (2007) Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol Res 37:135–145
Murphy P, Sharp A, Shin J, Gavrilyuk V, Dello Russo C, Weinberg G, Sharp FR, Lu A, Heneka MT, Feinstein DL (2002) Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. J Neurosci Res 67:461–470
Perry D, Sang A, Yin Y, Zheng YY, Morel L (2011) Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011:271694
Pockley AG (2003) Heat shock proteins as regulators of the immune response. Lancet 362:469–476
Poulaki V, Iliaki E, Mitsiades N, Mitsiades CS, Paulus YN, Bula DV, Gragoudas ES, Miller JW (2007) Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J 21:2113–2123
Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE (2008) Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 58:3765–3775
Rosman Z, Shoenfeld Y, Zandman-Goddard G (2013) Biologic therapy for autoimmune diseases: an update. BMC Med 11:88
Shimp SK 3rd, Chafin CB, Regna NL, Hammond SE, Read MA, Caudell DL, Rylander M, Reilly CM (2012) Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol 9:255–266
Shukla HD, Pitha PM (2012) Role of hsp90 in systemic lupus erythematosus and its clinical relevance. Autoimmune Dis 2012:728605
Sorger PK, Pelham HR (1987) The glucose-regulated protein grp94 is related to heat shock protein hsp90. J Mol Biol 194:341–344
Srivastava P (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185–194
Stocki P, Dickinson AM (2012) The immunosuppressive activity of heat shock protein 70. Autoimmune Dis 2012:617213
Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549
Tukaj S, Kleszczyński K, Vafia K, Groth S, Meyersburg D, Trzonkowski P, Ludwig RJ, Zillikens D, Schmidt E, Fischer TW, Kasperkiewicz M (2013) Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. PLoS One 8, e70496
Tukaj S, Zillikens D, Kasperkiewicz M (2014a) Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations. J Inflamm (Lond) 11:10
Tukaj S, Tiburzy B, Manz R, de Castro MA, Orosz A, Ludwig RJ, Zillikens D, Kasperkiewicz M (2014b) Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses. Exp Dermatol 23:585–590
Tukaj S, Grüner D, Zillikens D, Kasperkiewicz M (2014c) Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes. Cell Stress Chaperones 19:887–894
Tukaj S, Hellberg L, Ueck C, Hänsel M, Samavedam U, Zillikens D, Ludwig R, Laskay T, Kasperkiewicz M (2015) Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita. Exp Dermatol 24:567–571
van Eden W, van der Zee R, Prakken B (2005) Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 5:318–330
Wieten L, Broere F, van der Zee R, Koerkamp EK, Wagenaar J, van Eden W (2007) Cell stress induced HSP are targets of regulatory T cells: a role for HSP inducing compounds as anti-inflammatory immuno-modulators? FEBS Lett 581:3716–3722
Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772
Yun TJ, Harning EK, Giza K, Rabah D, Li P, Arndt JW, Luchetti D, Biamonte MA, Shi J, Lundgren K, Manning A, Kehry MR (2011) EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol 186:563–575
Zhang H, Zhang L, Yu F, Liu Y, Liang Q, Deng G, Chen G, Liu M, Xiao X (2012) HSF1 is a transcriptional activator of IL-10 gene expression in RAW264.7 macrophages. Inflammation 35:1558–1566
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tukaj, S., Węgrzyn, G. Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies. Cell Stress and Chaperones 21, 213–218 (2016). https://doi.org/10.1007/s12192-016-0670-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12192-016-0670-z